In a small study of patients with hepatitis C and liver fibrosis that were treated with 1200 mg/day for twelve months, fibrosis was reduced by 30%. An assessment was by liver biopsy. Inflammatory indices improved 53% 46.
En un pequeño estudio en pacientes con hepatitis C y fibrosis hepática, con un tratamiento de 1.200 mg/día durante doce meses, la fibrosis se redujo en el 30% evaluada por biopsia hepática y los índices inflamatorios mejoraron 53% 46.